+
+
Stay Informed
TEER

MITRACLIP™ Transcatheter Edge-to-Edge Repair

MitraClip™ is the first minimally invasive TEER* therapy that delivers a life-changing treatment option for select patients with primary or secondary mitral regurgitation who would otherwise go untreated1-2. MitraClip is the standard of care in TMVr built on the only proven mitral valve therapy with over 20 years of experience, an extensive body of clinical evidence, and more than 200K patients treated worldwide.3

*TEER is also referred to TMVr (Transcatheter Mitral Valve Repair)

The MitraClip™ TMVr procedure

Built to Repair. Proven to Restore.

MitraClip delivers uncompromising performance in TEER and sets the standard in clinical outcomes. With each generation of MitraClip, Abbott remains at the forefront of therapeutic expertise, partnering with heart teams to help select patients with MR reclaim their lives.

A better quality of life is possible for your patients with MR


MitraClip™ transcatheter edge-to-edge repair (TEER) is a minimally invasive treatment option for select patients with:

  • Significant Primary MR patients who are at prohibitive surgical risk
  • Significant secondary MR patients who remain symptomatic despite maximally tolerated guideline-directed medical therapy (GDMT)
Scott, MitraClip TEER Patient

“Scott is a lifelong athlete who found himself on the sidelines with significant mitral regurgitation. Learn about his experience receiving MitraClip therapy and his journey back to an active lifestyle.”

This testimonial relates an account of an individual’s response to the treatment. This patient’s account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.

The catalyst for a significant evolution in MR guidelines

Transcatheter edge-to-edge repair (TEER) therapy is now recommended by both the 2022 AHA/ACC/HFSA Guideline4 and the 2020 ACC/AHA Guideline5 for select primary and secondary* MR patients. Determining the severity of MR is an important factor in the management of the condition. The guidelines4,5 support aggressive monitoring and early action, with the goal of preventing complications due to LV volume overload.4

As the world's first TEER therapy, MitraClip™ is the only US-approved TEER therapy for both primary and secondary MR and ​ has served as the foundation for TEER recommendations.4,5
 

Severe MR is vastly undertreated

  • Surgical intervention not offered or denied
    Severe MR is vastly undertreated with no surgical intervention


    49% of patients with symptomatic severe MR were not operated due to age, co-morbidities, or impaired LV.6 If left untreated, MR initiates a cascade of events leading to death, with 1-year mortality up to 57%7

IDENTIFYING PATIENTS FOR MITRACLIP THERAPY


Transcatheter Mitral Valve Repair Patient Selection
Criteria Guide
 

DOWNLOAD NOW

Find a MitraClip certified
physician near me

Use this tool to refer a patient or consult with a certified implanting physician near you.

Show nearest:
Filter by:
TAILORED. OPTIMIZED. PROVEN.

Tailored. Optimized. Proven.
MitraClip™ G4

MitraClip TEER system’s dedicated design for the mitral anatomy optimizes navigation for consistent clinical results. Its proven performance and tailored treatment options allow it to treat the broadest range of mitral anatomies.

  • Broad range of sizes for tailored treatment9-11

    MitraClip G4 offers 4 Clip sizes to help tailor repair based on patient mitral valve anatomy.

    • G4 NT is the original MitraClip NT/NTR Clip size
    • G4 XT is the equivalent of XTR, with Clip arms that are 3 mm longer than G4 NT and allow for easier grasping due to better reach**
       

    The G4 NTW and XTW clips have a 50% wider grasping area than the NT and XT clips respectively. They are designed to tailor the treatment and further reduce MR with 4 Clip options. **

  • Treat more patients with more options8-11

    MitraClip successfully treats a broad range of valve anatomies in real world use8-11

    Significant and durable MR reduction achieved in patients with complex anatomies9

    90.3% of complex subjects achieved MR <1+ at 1 year.9


    "This was the best MitraClip case we have ever done … Gen 4 is a game-changer."

    Experienced Interventional Cardiologist commenting on MitraClip G4*
     

    *The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual’s experience and might not be representative of others.

    Ability to choose clip size based on each MV anatomy8,10

    CLIP SELECTION CONSIDERATIONS

    		FAVORS
    G4 NTW    		FAVORS
    G4 NT    		FAVORS
    G4 XTW    		FAVORS
    G4 XT
    Leaflet length < 9mm++  
    Leaflet length ≥ 9mm  ++
    Broad jet+ + 
    Smaller valve +  
    Larger valve+ ++

    MitraClip G4 clip selection recommendations were based on the initial clinical experience of an expert panel of physicians.8,10

    The EXPAND G4 real world study results further demonstrated clip selection preference and associated outcomes10:

    FOR PATIENTS WITH PMR

    XTW was used most often and achieved favorable MR reduction, particularly in patients with longer leaflets, large prolapse or wider jets, calcified leaflets or annulus and Barlow’s or bileaflet prolapse

    FOR PATIENTS WITH SMR

    NTW and XTW were used evenly across anatomies and achieved favorable MR reduction

    FOR ALL MR ETIOLOGIES

    NT and XT were used more frequently in multiple-clip cases and improved MR reduction

  • More options to confirm and optimize leaflet grasping with Controlled Gripper Actuation (CGA)1,**

    Controlled Gripper Actuation (CGA) provides the option to grasp leaflets simultaneously or independently, enabling the ability to confirm and optimize leaflet grasp.

    New gripper
    levers

    MitraClip G4 CGA with new gripper levers

    Simultaneous
    grasping

    MitraClip G4 CGA with simultaneous grasping

    Independent
    grasping

    MitraClip G4 CGA with independent grasping
  • Predictable procedure experience**

    The innovative Clip Delivery System is a highly maneuverable delivery catheter that is used to implant the MitraClip via a Steerable Guide Catheter.

    Precision and stability from a delivery system specifically designed for the mitral valve**
     

  • Increased procedural efficiency1,9

    Greater proportion
    of patients treated
    with 1 clip9

    MitraClip implantation

    Only 1 clip in
    65% of cases9
     

    Shortest
    device time to date in TEER9
     

    35 min. median
    device time9



    “In our institute, we have now reduced device time to ~20 min."

    Experienced Echocardiographer commenting on MitraClip G4*
     

    *The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual’s experience and might not be representative of others.

    Simplified procedural steps1

    • 40% reduction in system preparation steps
    • Simplified system deployment with minimal number of steps
       

LEARN MORE ABOUT MITRACLIP G4 FEATURES BY VISITING MITRACLIP.COM

Learn more

Webinars

Watch our webinars to learn more about how MitraClip can benefit physicians and help patients live longer, fuller lives.

VIEW All Webinars

MAT-2010220 v8.0 | Item approved for U.S. use only.

References

**Tests performed by and data on file at Abbott.

  1. MitraClip G4 System Instructions for Use.
  2. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after the transcatheter mitral valve repair. J Am Coll Cardiol. 2014;64(2):182-192.
  3. Data on file at Abbott.
  4. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association. Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Apr 01, 2022. Epublished DOI: 10.1016/j.jacc.2021.12.012
  5. Otto C, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Corrected version. Circ. 2021;143(5):e72-e227.
  6. Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358-1365.
  7. Cioffi G, Tarantini L, De Feo S, et al. Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. Eur J Heart Fail. 2005;7(7):1112-1117.
  8. Von Bardeleben RS, Rogers J, Mahoney P, et al. Real-World Outcomes of Fourth-Generation Mitral Transcatheter Repair: 30-Day Results From EXPAND G4. J Am Coll Cardiol Intv. 2023 Jun, 16 (12) 1463–1473.
  9. Von Bardeleben RS, et. al. Real-World Outcomes of Fourth-Generation MitralTranscatheter Repair, J Am Coll Cardiol Intv. 2023 Jun, 16 (12) 1463–1473.
  10. Maisano F, Clip Selection Strategy with 4th Generation MitraClipTM: Evidence-Based Recommendations from the Global EXPAND G4 Study. Data presented at PCR London Valve 2022.
  11. Rogers JH, et al. Expanding the Spectrum of TEER Suitability: Evidence from the EXPAND G4 Post Approval Study. JACC Cardiovasc Interv, 2023, 16(12): 1474-1485.
  12. Kar S, et al. Contemporary Outcomes Following Transcatheter Edge-to-Edge Repair: 1-Year Results from the EXPAND Study, JACC Cardiovasc Interv, 2023, 16(5): 589-602.
Important Safety Information

Rx Only

MITRACLIP DELIVERY SYSTEMS

INDICATION FOR USE
 

  • The MitraClip™ G4 System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
  • The MitraClip™ G4 System, when used with maximally tolerated guideline-directed medical therapy (GDMT), is indicated for the treatment of symptomatic, moderate-to-severe or severe secondary (or functional) mitral regurgitation (MR; MR ≥ Grade III per American Society of Echocardiography criteria) in patients with a left ventricular ejection fraction (LVEF) ≥ 20% and ≤ 50%, and a left ventricular end systolic dimension (LVESD) ≤ 70 mm whose symptoms and MR severity persist despite maximally tolerated GDMT as determined by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease.

CONTRAINDICATIONS

The MitraClip G4 System is contraindicated in patients with the following conditions: Patients who cannot tolerate, including allergy or hypersensitivity to, procedural anticoagulation or post procedural anti-platelet regime; Patients with known hypersensitivity to clip components (nickel / titanium, cobalt, chromium, polyester), or with contrast sensitivity; Active endocarditis of the mitral valve; Rheumatic mitral valve disease; Evidence of intracardiac, inferior vena cava (IVC) or femoral venous thrombus.

POTENTIAL COMPLICATIONS AND ADVERSE EVENTS

The following ANTICIPATED EVENTS have been identified as possible complications of the MitraClip G4 procedure: Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials (nickel / titanium, cobalt, chromium, polyester), and drug reactions to anticoagulation, or antiplatelet drugs, Vascular access complications which may require transfusion or vessel repair including: wound dehiscence, catheter site reactions, Bleeding (including ecchymosis, oozing, hematoma, hemorrhage, retroperitoneal hemorrhage), Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation / rupture, vascular occlusion, Emboli (air thrombotic material, implant, device component); Peripheral Nerve Injury; Lymphatic complications; Pericardial complications which may require additional intervention, including: Pericardial effuse on, Cardiac tamponade, Pericarditis; Cardiac complications which may require additional interventions or emergency cardiac surgery, including: Cardiac perforation, Atrial septal defect; Mitral valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single Leaflet Device Attachment (SLDA), Thrombosis, Dislodgement of previously implanted devices, Tissue damage, Mitral valve stenosis, Persistent or residual mitral regurgitation, Endocarditis; Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, and unstable / stable angina); Venous thromboembolism (including deep vein thrombosis, pulmonary embolism, post procedure pulmonary embolism); Stroke / Cerebrovascular accident (CVA) and Transient Ischemic Attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction / failure / atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Blood cell disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Hypotension / hypertension; Infection including: Urinary Tract Infection (UTI), Pneumonia, Septicemia; Nausea / vomiting; Chest pain; Dyspnea; Edema; Fever or hyperthermia; Pain; Death; Fluoroscopy, Transesophageal echocardiogram (TEE) and Transthoracic echocardiogram (TTE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation; Esophageal perforation, Gastrointestinal bleeding.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. VISITOR INTERNATIONAL VISITOR

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+